Enlicitide

1. Enlicitide decreases LDL-C in humans (~60%).

   Review52weeks

   Oral PCSK9 inhibitors: closing the gap between potency and practicality · Current opinion in lipidology · 18 Sep 2026

LDL-C →

1. Enlicitide decreases non-high-density lipoprotein cholesterol in humans (MD: -49.42 pp (95% CI: -54.23 to -44.60)).

   Reviewhypercholesterolemia or heterozygous familial hypercholesterolemia

   Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis · Journal of cardiovascular development and disease · 20 Aug 2026

Non-high-density lipoprotein cholesterol →

1. Enlicitide decreases Apolipoprotein B in humans (MD: -47.95 pp (95% CI: -51.22 to -44.67)).

   Reviewhypercholesterolemia or heterozygous familial hypercholesterolemia

   Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis · Journal of cardiovascular development and disease · 20 Aug 2026

Apolipoprotein B →

1. Enlicitide decreases low-density lipoprotein cholesterol in humans (MD: -55.78 percentage points (95% CI: -61.15 to -50.42)).

   Reviewhypercholesterolemia or heterozygous familial hypercholesterolemia

   Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis · Journal of cardiovascular development and disease · 20 Aug 2026

Low-density lipoprotein cholesterol →